Glomerulonephritis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 44 pages report, published by Global Markets Direct

Keywords : Glomerulonephritis Therapeutic Products under Development, Key Players in Glomerulonephritis Therapeutics, Glomerulonephritis Pipeline Overview, Glomerulonephritis Pipeline, Glomerulonephritis Pipeline Assessment

Report ThumbnailSeptember-2013
Glomerulonephritis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Glomerulonephritis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glomerulonephritis. Glomerulonephritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Glomerulonephritis.
- A review of the Glomerulonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glomerulonephritis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Glomerulonephritis, H2 2013 7
  • Products under Development for Glomerulonephritis - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Glomerulonephritis, H2 2013 7
  • Products under Development for Glomerulonephritis - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Baxter International Inc., H2 2013 16
  • Hansa Medical AB, H2 2013 17
  • Pharmalink AB, H2 2013 18
  • China Medical System Holdings Limited, H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Glomerulonephritis Therapeutics - Drug Profile Updates 36
  • Glomerulonephritis Therapeutics - Discontinued Products 38
  • Glomerulonephritis Therapeutics - Dormant Products 39
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Glomerulonephritis Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Glomerulonephritis 7
  • Glomerulonephritis Therapeutics under Development by Companies 9
  • Glomerulonephritis Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Glomerulonephritis Therapeutics - Products under Development by Companies 14
  • Glomerulonephritis Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Glomerulonephritis Therapeutics Development 16
  • Baxter International Inc. 16
  • Hansa Medical AB 17
  • Pharmalink AB 18
  • China Medical System Holdings Limited 19
  • Glomerulonephritis - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • budesonide - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • aliskiren - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • simvastatin - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • CMS010-26 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • BAX-69 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • EndoS - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • 3-Acetyl-5-Methyltetronic Acid - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • AVX-235 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Drug For Rapidly Progressive Glomerulonephritis - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Glomerulonephritis Therapeutics - Drug Profile Updates 36
  • Glomerulonephritis Therapeutics - Discontinued Products 38
  • Glomerulonephritis Therapeutics - Dormant Products 39
  • Glomerulonephritis - Product Development Milestones 40
  • Featured News & Press Releases 40
  • Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 40
  • Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 40
  • Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 41
  • Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 41
  • Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 42
  • Appendix 43
  • Methodology 43
  • Coverage 43
  • Secondary Research 43
  • Primary Research 43
  • Expert Panel Validation 43
  • Contact Us 44
  • Disclaimer 44

Please select a license type

Share

Related Products

Global Markets DirectGlomerulonephritis - Pipeline Review, H2 2013Product ThumbnailGlomerulonephritis - Pipeline Review, H2 2013, Industry ReportProduct #: 113319
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved